2026-04-29T04:09:47Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/251732025-12-18T13:00:43Zcom_20.500.12105_2173com_20.500.12105_2051col_20.500.12105_19597

00925njm 22002777a 4500 dc Gómez-Aleza, C author González-Suárez, E author 2021-05-14 RANK signaling in mouse mammary tumor cells exerts an immunosuppressive environment by promoting the infiltration of pro-tumorigenic neutrophils and preventing CD8 T cell recruitment. Single-agent denosumab led to an increased tumor immune infiltration by lymphocytes and CD8 + T cells in breast cancer patients, supporting the immunomodulatory role of RANK signaling. Oncoimmunology . 2021 May 14;10(1):1923156. https://hdl.handle.net/20.500.12105/25173 34026334 Oncoimmunology RANK RANKL breast cancer denosumab immunotherapy Inhibition of RANK signaling as a potential immunotherapy in breast cancer.